glipizide ER / Generic mfg. - LARVOL DELTA

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: University of Michigan | Suspended ➔ Recruiting

Enrollment open • Gastrointestinal Disorder

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Suspended | Sponsor: University of Michigan | Trial completion date: Sep 2025 ➔ Sep 2026 | Recruiting ➔ Suspended | Trial primary completion date: Jul 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Trial suspension • Gastrointestinal Disorder

GASTROINTESTINAL INTUBATION USING A MULTI-PORT ASPIRATION CATHETER TO STUDY DRUG RELEASE OF EXTENDED-RELEASE GLIPIZIDE DRUG PRODUCTS IN THE GASTROINTESTINAL TRACT OF HEALTHY HUMANS (DDW 2024) - "ConclusionsGlipizide concentrations were measurable in different regions of the GI tract and plasma concentrations for two glipizide drug products were within a similar range at 7 hours. Serial fluid sampling from the GI tract using intubation is feasible and may help inform in vivo drug release performance."

Clinical • Intubation • Gastrointestinal Disorder • Hypoglycemia

Novel Use of Dual GIP/GLP-1 Receptor Agonist in HNF4A-MODY (ENDO 2024) - "He was then transitioned from dulaglutide to tirzepatide 5 mg once weekly for 4 weeks, 7.5 mg once weekly for 4 weeks, then 10 mg once weekly. He has been maintained on tirzepatide 10 mg once weekly, glipizide extended release 10 mg once daily, and metformin 1,000 mg twice daily without significant side effects...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO."

Diabetes • Hypoglycemia • Metabolic Disorders • HNF1A • PDX1

Uncommon dermatologic manifestation (paronychia) in a cat with diabetes mellitus. (PubMed, Top Companion Anim Med) - "Glipizide (Glucotrol XL, Pfizer, Indonesia) 2.5 mg orally twice daily was prescribed...This is the first report of a diabetic cat with dermatologic changes to the skin and claw regions. As the diabetes mellitus went into clinical remission, so too did the dermatologic manifestations, even without any specific dermatologic treatment."

Journal • Dermatology • Diabetes • Metabolic Disorders

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: University of Michigan | Trial completion date: Sep 2023 ➔ Sep 2025 | Trial primary completion date: Jul 2023 ➔ Jul 2025

Trial completion date • Trial primary completion date • Gastrointestinal Disorder

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia (clinicaltrials.gov) - P4 | N=100 | Completed | Sponsor: Cook County Health | Unknown status ➔ Completed

Trial completion • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Open-Label, Randomized, Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: University of Michigan

Clinical • New P1 trial • Gastrointestinal Disorder

[VIRTUAL] A Bizarre Case of Recurrent Hypoglycemia (ENDO 2021) - "We hereby present an intriguing case of recurrent hypoglycemia in relation to it.Case presentation: A 65 year-old white male with surgically induced panhypopituitarism on replacement hydrocortisone, levothyroxine and testosterone was transferred to our hospital with recurrent serious hypoglycemic episodes...An online search identified tablets as Glucotrol-XL 10 mg and hydrocortisone 10 mg...Four medications or medication classes were implicated in 67% of hospitalizations: warfarin, insulins, oral antiplatelet agents, and oral hypoglycemic agents...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021."

Clinical • Endocrine Disorders • Hypoglycemia • Severe Hypoglycemia

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) (clinicaltrials.gov) - P3; N=213; Completed; Sponsor: Merck Sharp & Dohme Corp.; Active, not recruiting ➔ Completed

Trial completion • Biosimilar • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Renal Disease

Efficacy and Safety of Premixed Human Insulin Combined with Sulfonylureas in Type 2 Diabetic Patients Previously Poorly Controlled with Insulin. (PubMed, Diabetes Ther) - "Insulin combined with sulfonylureas could improve glycemic control without increasing daily insulin dose and adverse events. Based on our results, we consider the combination of premixed insulin and sulfonylureas to be effective and safe for the treatment of T2DM."

Clinical • Journal